Grifols, S.A. Overview
Pro stress-test →Grifols operates as a plasma therapeutic company in Spain, the United States, Canada, and internationally. As the European leader and third largest worldwide producer of blood plasma–based products, the company also operates in transfusion medicine and clinical diagnostic technologies. The company addresses critical healthcare needs through specialized protein-based therapies.
Strategic Profile
Pro stress-test →Grifols is focused on four main therapeutic areas: immunology, infectious diseases, pulmonology and critical care. The company's plasma fractionation capacity is currently at 22 million liters per year, with the aim of reaching 26 million by 2026, as part of efforts to meet growing demand for plasma-derived medicines. Strategic positioning centers on expanding production capacity and therapeutic innovation in plasma-derived solutions.
Competitive Landscape
Pro stress-test →United Therapeutics, BioMarin Pharmaceutical, Taibang Biological Group, Alnylam Pharmaceuticals, and CSL Behring are among Grifols' competitors. Grifols maintains a competitive edge as the dominant European and third-largest global plasma-derived medicine manufacturer, though it faces emerging competitive threats particularly in select therapeutic areas.
Industry Context
Grifols, S.A. operates in Specialty Biopharmaceuticals / Plasma Therapeutics.
Key facts
Founded: 1909 · Headquarters: Barcelona, Spain · Employees: 23,800 · Revenue: $7.52B · Market cap: $7.9B